NASDAQ:LXRX

Lexicon Pharmaceuticals News Headlines

$5.05
-0.16 (-3.07 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$4.91
Now: $5.05
$5.25
50-Day Range
$5.07
MA: $6.31
$7.60
52-Week Range
$1.03
Now: $5.05
$9.65
Volume925,988 shs
Average Volume4.45 million shs
Market Capitalization$728.99 million
P/E RatioN/A
Dividend YieldN/A
Beta2.09

Headlines

Lexicon Pharmaceuticals (NASDAQ LXRX) News Headlines Today

SourceHeadline
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Gap Up to $5.07Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Gap Up to $5.07
americanbankingnews.com - April 13 at 11:10 AM
Lexicon Pharmaceuticals to Participate in the 20th Annual Needham Virtual Healthcare ConferenceLexicon Pharmaceuticals to Participate in the 20th Annual Needham Virtual Healthcare Conference
finance.yahoo.com - April 8 at 6:01 PM
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Short Interest UpdateLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Short Interest Update
americanbankingnews.com - April 2 at 1:08 AM
Lexicon Pharmaceuticals (NASDAQ:LXRX) versus Crinetics Pharmaceuticals (NASDAQ:CRNX) Financial ReviewLexicon Pharmaceuticals (NASDAQ:LXRX) versus Crinetics Pharmaceuticals (NASDAQ:CRNX) Financial Review
americanbankingnews.com - March 30 at 2:36 PM
Lexicon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:LXRX)Lexicon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:LXRX)
americanbankingnews.com - March 30 at 8:44 AM
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Given Average Rating of "Hold" by AnalystsLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Given Average Rating of "Hold" by Analysts
americanbankingnews.com - March 28 at 2:48 AM
Investors Buy High Volume of Lexicon Pharmaceuticals Call Options (NASDAQ:LXRX)Investors Buy High Volume of Lexicon Pharmaceuticals Call Options (NASDAQ:LXRX)
americanbankingnews.com - March 25 at 6:38 AM
Implied Volatility Surging for Lexicon Pharmaceuticals (LXRX) Stock OptionsImplied Volatility Surging for Lexicon Pharmaceuticals (LXRX) Stock Options
finance.yahoo.com - March 15 at 1:49 PM
Lexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats on Q4 2020 Results - Earnings Call TranscriptLexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com - March 12 at 3:20 PM
Lexicon: Q4 Earnings SnapshotLexicon: Q4 Earnings Snapshot
finance.yahoo.com - March 10 at 6:47 PM
Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Clinical UpdateLexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Clinical Update
finance.yahoo.com - March 10 at 6:47 PM
Earnings Preview: Lexicon PharmaceuticalsEarnings Preview: Lexicon Pharmaceuticals
benzinga.com - March 9 at 2:08 PM
Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2020 Financial Results Conference Call and Webcast on March 10, 2021Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2020 Financial Results Conference Call and Webcast on March 10, 2021
finance.yahoo.com - March 4 at 6:53 PM
Lexicons Sotagliflozin: New Approach To Safety May Make Approval EasierLexicon's Sotagliflozin: New Approach To Safety May Make Approval Easier
seekingalpha.com - March 2 at 11:33 AM
Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Beat EstimatesSarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Beat Estimates
finance.yahoo.com - March 2 at 11:33 AM
Perrigo (PRGO) Misses on Q4 Earnings, to Sell Generic UnitPerrigo (PRGO) Misses on Q4 Earnings, to Sell Generic Unit
finance.yahoo.com - March 1 at 12:36 PM
Repligen (RGEN) to Report Q4 Earnings: Whats in the Cards?Repligen (RGEN) to Report Q4 Earnings: What's in the Cards?
finance.yahoo.com - February 11 at 12:59 PM
Should You Buy Lexicon Pharmaceuticals Stock?Should You Buy Lexicon Pharmaceuticals Stock?
fool.com - February 6 at 6:58 AM
News Flash: Analysts Just Made An Incredible Upgrade To Their Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) ForecastsNews Flash: Analysts Just Made An Incredible Upgrade To Their Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Forecasts
finance.yahoo.com - January 31 at 12:39 PM
Got $5,000 and 5 Years to Wait? Buy These 5 Hot Biotech Stocks NowGot $5,000 and 5 Years to Wait? Buy These 5 Hot Biotech Stocks Now
finance.yahoo.com - January 29 at 8:25 AM
Why Lexicon Pharmaceuticals Stock Is Down TodayWhy Lexicon Pharmaceuticals Stock Is Down Today
fool.com - January 16 at 1:35 AM
Lexicon (LXRX) Soars on FDA Permission for Sotagliflozin NDALexicon (LXRX) Soars on FDA Permission for Sotagliflozin NDA
finance.yahoo.com - January 15 at 11:43 AM
FDA Expands Approved Use Of PFEs Xalkori, LXRX Soars On Sotagliflozin Update, BCYC Hits New HighFDA Expands Approved Use Of PFE's Xalkori, LXRX Soars On Sotagliflozin Update, BCYC Hits New High
nasdaq.com - January 15 at 1:21 AM
Why Lexicon Pharmas Stock Is Surging Higher TodayWhy Lexicon Pharma's Stock Is Surging Higher Today
msn.com - January 14 at 8:20 PM
Why Lexicon Pharmaceuticals Stock Doubled and Then Some on ThursdayWhy Lexicon Pharmaceuticals Stock Doubled and Then Some on Thursday
msn.com - January 14 at 8:20 PM
Mid-Day Market Update: Volt Information Sciences Drops After Q4 Results; Lexicon Pharmaceuticals Shares JumpMid-Day Market Update: Volt Information Sciences Drops After Q4 Results; Lexicon Pharmaceuticals Shares Jump
markets.businessinsider.com - January 14 at 3:17 PM
Is Lexicon Pharma a Stock to Buy After 90% Runup and FDA Nod?Is Lexicon Pharma a Stock to Buy After 90% Runup and FDA Nod?
msn.com - January 14 at 3:17 PM
Stock Alert: Lexicon Pharmaceuticals Surges 35%Stock Alert: Lexicon Pharmaceuticals Surges 35%
nasdaq.com - January 14 at 3:17 PM
Lexicon Pharmaceuticals and NantKwest among healthcare gainers; Cassava Sciences among losersLexicon Pharmaceuticals and NantKwest among healthcare gainers; Cassava Sciences among losers
seekingalpha.com - January 14 at 11:43 AM
Lexicon Pharmaceuticals Provides Regulatory Update on Sotagliflozin in Heart FailureLexicon Pharmaceuticals Provides Regulatory Update on Sotagliflozin in Heart Failure
finance.yahoo.com - January 14 at 9:37 AM
Lexicon Pharmaceuticals to Participate in the 39th Annual J.P. Morgan Healthcare ConferenceLexicon Pharmaceuticals to Participate in the 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 6 at 12:23 PM
Lexicon (LXRX) Starts Dosing in Post-Herpetic Neuralgia StudyLexicon (LXRX) Starts Dosing in Post-Herpetic Neuralgia Study
finance.yahoo.com - January 4 at 12:36 PM
Lexicon Pharma Kicks Off Dosing In Phase 2 Study Of Post-Herpetic Neuralgia TreatmentLexicon Pharma Kicks Off Dosing In Phase 2 Study Of Post-Herpetic Neuralgia Treatment
nasdaq.com - January 1 at 8:25 AM
Lexicon Pharmaceuticals Announces Commencement of Dosing in Phase 2 Clinical Study of LX9211 in Post-Herpetic NeuralgiaLexicon Pharmaceuticals Announces Commencement of Dosing in Phase 2 Clinical Study of LX9211 in Post-Herpetic Neuralgia
finance.yahoo.com - December 31 at 1:47 PM
Moving Average Crossover Alert: Lexicon Pharmaceuticals (LXRX)Moving Average Crossover Alert: Lexicon Pharmaceuticals (LXRX)
finance.yahoo.com - December 31 at 7:53 AM
Lexicon Pharma Inks Data Collaboration Deal With AC BioscienceLexicon Pharma Inks Data Collaboration Deal With AC Bioscience
nasdaq.com - December 17 at 1:45 PM
After Hours Market: Wunong Net, Lexicon Pharma, Scopus BioPharma Gain; Upstart Holdings SlipsAfter Hours Market: Wunong Net, Lexicon Pharma, Scopus BioPharma Gain; Upstart Holdings Slips
markets.businessinsider.com - December 16 at 5:08 PM
Lexicon Pharmaceuticals Enters Data Collaboration With AC BioscienceLexicon Pharmaceuticals Enters Data Collaboration With AC Bioscience
finance.yahoo.com - December 16 at 5:08 PM
Lexicon Buoyed By Renewed Enthusiasm For The PipelineLexicon Buoyed By Renewed Enthusiasm For The Pipeline
seekingalpha.com - December 15 at 6:20 PM
Is LXRX A Good Stock To Buy Now?Is LXRX A Good Stock To Buy Now?
finance.yahoo.com - December 12 at 7:23 PM
Why Lexicon Pharmaceuticals Flopped on FridayWhy Lexicon Pharmaceuticals Flopped on Friday
fool.com - December 11 at 6:15 PM
Lexicon Pharma: LX9211 Receives Fast Track Designation - Quick FactsLexicon Pharma: LX9211 Receives Fast Track Designation - Quick Facts
nasdaq.com - December 11 at 12:22 PM
Lexicon Pharmaceuticals Receives Fast Track Designation From the FDA for LX9211 for Diabetic Peripheral Neuropathic PainLexicon Pharmaceuticals Receives Fast Track Designation From the FDA for LX9211 for Diabetic Peripheral Neuropathic Pain
finance.yahoo.com - December 11 at 12:22 PM
Lexicon Announces Offering of Common StockLexicon Announces Offering of Common Stock
finance.yahoo.com - December 11 at 12:22 PM
Is the Options Market Predicting a Spike in Lexicon Pharmaceuticals (LXRX) Stock?Is the Options Market Predicting a Spike in Lexicon Pharmaceuticals (LXRX) Stock?
finance.yahoo.com - December 9 at 6:06 PM
Why Lexicon Pharmaceuticalss Stock is Up During Todays SessionWhy Lexicon Pharmaceuticals's Stock is Up During Today's Session
benzinga.com - December 8 at 4:05 PM
Thinking about buying stock in Tesla, FuelCell Energy, Lexicon Pharmaceuticals, Electrameccanica Vehicles, or Outlook Therapeutics?Thinking about buying stock in Tesla, FuelCell Energy, Lexicon Pharmaceuticals, Electrameccanica Vehicles, or Outlook Therapeutics?
marketwatch.com - November 17 at 6:07 PM
Why Lexicon Pharmaceuticals Stock Is Trading Higher TodayWhy Lexicon Pharmaceuticals Stock Is Trading Higher Today
feeds.benzinga.com - November 17 at 11:30 AM
41 Stocks Moving in Tuesdays Pre-Market Session41 Stocks Moving in Tuesday's Pre-Market Session
msn.com - November 17 at 8:00 AM
Lexicon Pharma +45% after drug shows benefits for heart patientsLexicon Pharma +45% after drug shows benefits for heart patients
seekingalpha.com - November 17 at 8:00 AM
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.